Abstract
To investigate the immunomodulatory activities of phytocompounds for potential therapeutics, we devised an in vivo, transgenic, human cytokine gene promoter assay using defined epidermal skin cells as test tissue. Test compounds were topically applied to mouse skin before or after gene gun transfection, using a cytokine gene promoter-driven luciferase reporter. Croton oil, an inflammation inducer, induced transgenic GM-CSF and TNF-α promoter activities in skin epidermis 6-fold and 3.4-fold, respectively; however, it produced a less than 1.5-fold and 1.7-fold change in IL-1β and IL-18 promoter activity, respectively. The phytocompound shikonin drastically inhibited inducible GM-CSF promoter activity. However, a fraction of Dioscorea batatas extract significantly increased the GM-CSF promoter activity in normal and inflamed skin. Shikonin suppressed the transcriptional activity of GM-CSF promoter by inhibiting the binding of TFIID protein complex (TBP) to TATA box. Our results demonstrate that this in vivo transgenic promoter activity assay system is cytokine gene-specific, and highly responsive to pro-inflammatory or anti-inflammatory stimuli. Currently it is difficult to profile the expression and cross-talk of various types of cytokines in vivo. This investigation has established a bona fide in vivo, in situ, immune tissue system for research into cytokine response to inflammation.
Similar content being viewed by others
References
Koop CE (2002) The future of medicine. Science 295:233
Borchers AT, Keen CL, Stern JS, Gershwin ME (2000) Inflammation and native American medicine: the role of botanicals. Am J Clin Nutr 72:339–347
Hengge UR, Benninghoff B, Ruzicka T, Goos M (2001) Topical immunomodulators–progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 1:189–198
Tak PP, Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107:7–11
Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135–142
Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, Pasco DS (2001) Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription. J Biomol Screen 6:101–110
Williams IR, Kupper TS (1996) Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci 58:1485–1507
Wittmann M, Werfel T (2006) Interaction of keratinocytes with infiltrating lymphocytes in allergic eczematous skin diseases. Curr Opin Allergy Clin Immunol 6:329–334
Yang NS, McCabe DE, Swain WF (1996) Methods for particle-mediated gene transfer into skin. In: Robbins P (ed) Methods in molecular medicine, gene therapy protocols. Totowa, Humana Press Inc, pp 281–296
Armitage JO (1998) Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92:4491–4508
Smith PD, Lamerson CL, Wong HL, Wahl LM, Wahl SM (1990) Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis 161:999–1005
Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HSW, Das G, Devadas S (2006) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Res 16:126–133
Liu XY, Gu JF (2006) Targeting gene-virotherapy of cancer. Cell Res 16:25–30
Berinstein NL (2007) Enhancing cancer vaccines with immunomodulators. Vaccine 25:B72–B88
Dranoff G (2002) GM-CSF-based cancer vaccines. Immunol Rev 188:147–154
Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM (2001) Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 7:952–961
Pastore S, Belasio EF, Albanesi C, Chinni LM (1997) Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. J Clin Invest 99:3009–3017
Pastore S, Giustizieri ML, Mascia F, Giannetti A, Kaushansky K, Girolomoni G (2000) Dysregulated activation of activator protein 1 in keratinocytes of atopic dermatitis patients with enhanced expression of granulocyte/macrophage-colony stimulating factor. J Invest Dermatol 115:1134–1143
Mann A, Breuhahn K, Schirmacher P, Wilhelmi A, Beyer C, Rosenau A, Ozbek S, SR J, Blessing M (2001) Up- and down-regulation of granulocyte/macrophage-colony stimulating factor activity in murine skin increase susceptibility to skin carcinogenesis by independent mechanisms. Cancer Res 61:2311–2319
McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, Reid HH, BCC A (2001) Granulocyte macrophage colony-stimulating factor: A new putative therapeutic target in multiple sclerosis. J Exp Med 194:873–881
Corsini E, Galli CL (2000) Epidermal cytokines in experimental contact dermatitis. Toxicology 142:203–211
Chiang YM, Chuang DY, Wang SY, Kuo YH, Tsai PW, Shyur LF (2004) Metabolite profiling and chemopreventive bioactivity of plant extracts from Bidens pilosa. J Ethnopharmacol 95:409–419
Perry NB, Burgess EJ, Glennie VL (2001) Echinacea standardization: analytical methods for phenolic compounds and typical levels in medicinal species. J Agric Food Chem 49:1702–1706
Chen X, Oppenheim J, Zack Howard OM (2001) Shikonin, a component of anti-inflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1. Int Immunopharmacol 1:229–236
Staniforth V, Shyur LF, Yang NS (2004) Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor promoter in vivo. J Biol Chem 279:5877–5885
Haas J, Lipkow T, Mohamadzadeh M, Kolde G, Knop J (1992) Induction of inflammatory cytokines in murine keratinocytes upon in vivo stimulation with contact sensitizers and tolerizing analogues. Exp Dermatol 1:76–83
Leung DY (1997) Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 107 Suppl 1:25–30
Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, Hank JA, Mahvi DM, Albertini MR (2007) A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 13:540–549
Wilmer JL, Burleson FG, Kayama F, Kanno J, Luster MI (1994) Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin. J Invest Dermatol 102:915–922
Smith PJ, Cousins DJ, Jee YK, Staynov DZ, Lee TH, Lavender P (2001) Suppression of granulocyte-macrophage colony-stimulating factor expression by glucocorticoids involves inhibition of enhancer function by the glucocorticoid receptor binding to composite NF-AT/Activator Protein-1 elements. J Immunol 167:2502–2510
Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DYM (2003) Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171:3262–3269
Wakelin SH (2001) Contact urticaria. Clin Exp Dermatol 26:132–136
Watanabe H, Unger M, Tuvel B, Wang B, Sauder DN (2002) Contact hypersensitivity: the mechanism of immune responses and T cell balance. J Interf Cytok Res 22:407–412
Muller G, Knop J, Enk AH (1996) Is cytokine expression responsible for differences between allergens and irritants? Am J Contact Dermat 7:177–184
Gray JG, Chandra G, Clay WC, Stinnett SW, Haneline SA, Lorenz JJ, Patel IR, Wisely GB, Furdon PJ, Taylor JD (1993) A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1 beta gene is necessary for induction in U937 and THP-1 monocytic cell lines. Mol Cell Biol 13:6678–6689
Clark BD, Collins KL, Gandy MS, Webb AC, Auron AE (1986) Genomic sequence for human prointerleukin 1 beta: possible evolution from a reverse transcribed prointerleukin 1 alpha gene. Nucleic Acids Res 14:7897–7914
Giedraitis V, He B, Huang WX, Hillert J (2001) Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112:146–152
Takashiba S, Shapira L, Amar S, Van Dyke TE (1993) Cloning and characterization of human TNF alpha promoter region. Gene 131:307–308
Jenkins F, Cockerill PN, Bohmann D, Shannon MF (1995) Multiple signals are required for function of the human granulocyte-macrophage colony-stimulating factor gene promoter in T cells. J Immunol 155:1240–1251
Acknowledgements
This work was supported by research grants of No. 91S701911 and No. 94S-0402 from the National Science and Technology Program for Agricultural Biotechnology, and an institutional grant from Academia Sinica, Taiwan, R.O.C.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Su, PF., Staniforth, V., Li, CJ. et al. Immunomodulatory effects of phytocompounds characterized by in vivo transgenic human GM-CSF promoter activity in skin tissues. J Biomed Sci 15, 813–822 (2008). https://doi.org/10.1007/s11373-008-9266-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11373-008-9266-7